Zura Bio (NASDAQ:ZURA) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Zura Bio (NASDAQ:ZURA) announced its quarterly earnings data on Tuesday. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01), Zacks reports.

Zura Bio Stock Performance

NASDAQ ZURA opened at $5.86 on Tuesday. The business has a 50 day simple moving average of $4.84 and a 200 day simple moving average of $5.41. Zura Bio has a 52-week low of $1.39 and a 52-week high of $7.44. The stock has a market cap of $556.09 million, a price-to-earnings ratio of -5.41 and a beta of -0.02.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ZURA shares. Wedbush restated an “outperform” rating and set a $15.00 target price on shares of Zura Bio in a report on Wednesday, July 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Monday, July 6th. Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Finally, William Blair began coverage on shares of Zura Bio in a research note on Wednesday, July 8th. They set an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.75.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Scientech Research LLC acquired a new position in shares of Zura Bio in the third quarter valued at approximately $45,000. Dimensional Fund Advisors LP bought a new stake in shares of Zura Bio in the fourth quarter valued at about $123,000. Squarepoint Ops LLC acquired a new position in shares of Zura Bio during the third quarter worth about $109,000. Qube Research & Technologies Ltd acquired a new stake in Zura Bio in the 3rd quarter valued at approximately $138,000. Finally, Quadrature Capital Ltd bought a new stake in Zura Bio in the 4th quarter valued at approximately $192,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.